Missing data handling technique in joint modeling context

[1]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[2]  F. Hsieh,et al.  Joint Modeling of Survival and Longitudinal Data: Likelihood Approach Revisited , 2006, Biometrics.

[3]  Geert Verbeke,et al.  Fully exponential Laplace approximations for the joint modelling of survival and longitudinal data , 2009 .

[4]  Georgia Salanti,et al.  Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. , 2007, The Lancet. Oncology.

[5]  J. Denekamp,et al.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.

[6]  U. Dafni,et al.  Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer , 2009, Clinical Cancer Research.

[7]  J. Folkman,et al.  Angiogenesis and apoptosis. , 2003, Seminars in cancer biology.

[8]  A. Maraveyas,et al.  Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth , 2007, Acta oncologica.

[9]  M. Escobar.  Estimating Normal Means with a Dirichlet Process Prior , 1994 .

[10]  Marie Davidian,et al.  A Semiparametric Likelihood Approach to Joint Modeling of Longitudinal and Time‐to‐Event Data , 2002, Biometrics.

[11]  R. Prentice.  Covariate measurement errors and parameter estimation in a failure time regression model , 1982 .

[12]  Qing-Bin Lu.  Molecular reaction mechanisms of combination treatments of low-dose cisplatin with radiotherapy and photodynamic therapy. , 2007, Journal of medicinal chemistry.

[13]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[14]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[15]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  M. Wulfsohn,et al.  A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.

[17]  Anastasios A. Tsiatis,et al.  A semiparametric estimator for the proportional hazards model with longitudinal covariates measured with error , 2001 .

[18]  J. Copas,et al.  Inference for Non‐random Samples , 1997 .

[19]  S. Arya,et al.  A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. , 2015, Oral oncology.

[20]  L. Saltz.  Progress in cancer care: the hope, the hype, and the gap between reality and perception. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Thomas,et al.  Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. , 1996, Statistics in medicine.

[22]  Jane-Ling Wang,et al.  Modeling Longitudinal Data with Nonparametric Multiplicative Random Effects Jointly with Survival Data , 2008, Biometrics.

[23]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[24]  L. Fisher,et al.  Time-dependent covariates in the Cox proportional-hazards regression model. , 1999, Annual review of public health.

[25]  J. Ibrahim,et al.  A Flexible B‐Spline Model for Multiple Longitudinal Biomarkers and Survival , 2005, Biometrics.

[26]  Wei Liu,et al.  Analysis of Longitudinal and Survival Data: Joint Modeling, Inference Methods, and Issues , 2012 .

[27]  H. Hausmaninger,et al.  Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[29]  A. Gallant,et al.  Semi-nonparametric Maximum Likelihood Estimation , 1987 .

[30]  T. Ferguson.  A Bayesian Analysis of Some Nonparametric Problems , 1973 .

[31]  M. Escobar,et al.  Bayesian Density Estimation and Inference Using Mixtures , 1995 .

[32]  Dimitris Rizopoulos,et al.  A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time‐to‐event , 2011, Statistics in medicine.

[33]  Joseph G. Ibrahim,et al.  BAYESIAN METHODS FOR JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA WITH APPLICATIONS TO CANCER VACCINE TRIALS , 2004 .

[34]  C. Marquette,et al.  Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer , 2014, British Journal of Cancer.

[35]  Jun Liang,et al.  Low‐dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? , 2010, International journal of experimental pathology.

[36]  O. Scharovsky,et al.  Metronomic chemotherapy: changing the paradigm that more is better , 2009, Current oncology.

[37]  R. Kerbel,et al.  Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Lancelot F. James,et al.  Gibbs Sampling Methods for Stick-Breaking Priors , 2001 .

[39]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.